Literature DB >> 3944769

Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs.

J van Crugten, F Bochner, J Keal, A Somogyi.   

Abstract

Cimetidine reduces the renal clearances of the organic cations procainamide and n-acetylprocainamide in humans and in vitro preparations by inhibition of renal cationic proximal tubular secretion. The aim of this study was to investigate in humans the selectivity of cimetidine in altering the renal handling of three different organic ions as drug substances: anion (cephalothin), cation (ranitidine) and zwitterion (cephalexin). The study was conducted in six healthy subjects who received the above drugs as single doses with and without chronic cimetidine administration. Cimetidine had no statistically significant (P greater than .05) effect on cephalothin disposition including renal clearance, but significantly reduced the renal clearance of ranitidine by over 40% between 4 and 12 hr after administration, with a concomitant increase in ranitidine plasma concentrations and elimination half-life prolongation. In addition, the renal clearance of cephalexin was reduced by cimetidine by 27% between 1 and 2 hr, but there was no change in cephalexin plasma concentrations and elimination half-life. These findings confirmed the hypothesis that cimetidine-mediated inhibition of renal drug clearance in humans is selective for a common cationic secretory transport mechanism in the proximal tubule of the kidney, rather than a nonspecific action on renal function.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3944769

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  24 in total

Review 1.  Saturable pharmacokinetics in the renal excretion of drugs.

Authors:  C A van Ginneken; F G Russel
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 3.  Drug interactions at the renal level. Implications for drug development.

Authors:  P L Bonate; K Reith; S Weir
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

Review 4.  Renal transport of drugs: an overview of methodology with application to cimetidine.

Authors:  K M Giacomini; P H Hsyu; L G Gisclon
Journal:  Pharm Res       Date:  1988-08       Impact factor: 4.200

Review 5.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

6.  Inhibition and induction of metronidazole and antipyrine metabolism.

Authors:  S Loft; J Sonne; H E Poulsen; K T Petersen; B G Jørgensen; M Døssing
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Human placental transport of cimetidine.

Authors:  S Schenker; J Dicke; R F Johnson; L L Mor; G I Henderson
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

8.  Reduction of metformin renal tubular secretion by cimetidine in man.

Authors:  A Somogyi; C Stockley; J Keal; P Rolan; F Bochner
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335

9.  The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.

Authors:  Jennifer E Hibma; Arik A Zur; Richard A Castro; Matthias B Wittwer; Ron J Keizer; Sook Wah Yee; Srijib Goswami; Sophie L Stocker; Xuexiang Zhang; Yong Huang; Claire M Brett; Radojka M Savic; Kathleen M Giacomini
Journal:  Clin Pharmacokinet       Date:  2016-06       Impact factor: 6.447

10.  Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans.

Authors:  R Bendayan; J T Sullivan; C Shaw; R C Frecker; E M Sellers
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.